Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Public ClinicalTrials.gov record NCT00001337. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma
Study identification
- NCT ID
- NCT00001337
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Enrollment
- 348 participants
Conditions and interventions
Conditions
Interventions
- Biopsy Procedure
- CT Diagnostic Test
- Cyclophosphamide Drug
- Docusate Sodium + Sennosides Other
- Doxorubicin Drug
- Etoposide Drug
- Lactulose Other
- Laparotomy Procedure
- MRI Diagnostic Test
- Omeprazole Other
- Ondansetron Other
- PET scan Diagnostic Test
- Prednisone Drug
- Prochlorperazine Other
- Rituximab Biological
- Vincristine Drug
Procedure · Diagnostic Test · Drug + 2 more
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 7, 1993
- Primary completion
- May 23, 2024
- Completion
- May 23, 2024
- Last update posted
- Jun 21, 2025
1993 – 2024
United States locations
- U.S. sites
- 5
- U.S. states
- 4
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Holy Cross Hospital, Fort Lauderdale | Fort Lauderdale | Florida | 33308 | — |
| University of Maryland, Baltimore | Baltimore | Maryland | 21201-1595 | — |
| National Institutes of Health Clinical Center | Bethesda | Maryland | 20892 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| St. Luke's Roosevelt Hospital | New York | New York | 10025 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00001337, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 21, 2025 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00001337 live on ClinicalTrials.gov.